Belzutifan VHL RCC HK Prospective Registry
ConditionVHL - Von Hippel-Lindau Syndrome
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChinese University of Hong Kong
About this trial
This study aims to evaluate the Belzutifan's efficacy, drug safety, disease course, and the health-economic impact of the treatment to Von Hippel-Lindau (VHL) syndrome.
Eligibility criteria
Qualifiers
Adult patients (age 18 or above) with confirmed VHL-spectrum disease through clinical and/or genetic diagnosis.
The patient decided to use Belzutifan for their treatment.
Disqualifiers
Tumour requiring immediate resection.
Pregnancy or unwillingness to use contraception if of childbearing potential.
Uncontrolled comorbidities (e.g., active infection, severe cardiopulmonary disease).
Trial design
Treatments tested in this trial
- Not listed
Trial groups
100 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov